Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and potential effectiveness of an investigational drug called ENV-294 in adults with moderate to severe asthma. Participants in this study are already receiving background treatment with inhaled corticosteroids ICS and long-acting beta2-agonists LABA. The study aims to better understand how ENV-294 works and its impact on asthma control. Participants will be randomly assigned to receive either oral ENV-294 or a placebo once daily for 12 weeks. Before starting treatment, there is a screening period of up to 28 days to confirm eligibility. The study includes two groups one receiving ENV-294 tablets daily and the other receiving matching placebo tablets under the same conditions. Throughout the study, participants will attend visits for assessments to monitor safety, measure drug levels in the blood, and evaluate lung function and asthma control. The main outcome measured is the incidence and severity of adverse events from the first dose through about 16 weeks. Other evaluations include loss of asthma control events, time to loss of asthma control, and plasma concentrations of ENV-294. The total participation time includes screening and 12 weeks of treatment.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.